A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants With Congenital Protein C Deficiency

Takeda

Status

Enrolling

Conditions

Protein C Deficiency

Treatments

Drug: Freeze-dried Human Protein C Concentrate

Study type

Observational

Funder types

Industry

Identifiers

NCT06590974

jRCT2031240322 (Registry Identifier)

TAK-662-4002

Details and patient eligibility

About

This study is conducted in Japan of Freeze-dried Human Protein C Concentrate (TAK-662) used to treat participants with congenital protein C deficiency.

The main aim of the study is to evaluate for adverse events and effectiveness of congenital protein C deficiency (TAK-662).

During the study, participants with congenital protein C deficiency will be administered with TAK-662 intravenous injection in under routine normal practice. The investigators will evaluate adverse events due to TAK-662 for 12 months. For participants who will be administered in long-term supplementation of TAK-662 after acute treatment or short-term supplementation, the investigator will evaluate for 24 months as a maximum. The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.

Enrollment

7 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

- All participants with congenital protein C deficiency who are administered with Freeze-dried Human Protein C Concentrate (TAK-662).

Exclusion criteria

- None